Characteristics, empiric treatment, and clinical cure rates were compared between a Boston academic medical center (August 2013–January 2014). Clinical and microbiomized or emergency-department-attending adults with monomicrobial bacteriuria at detected by PCR for 142 non-duplicate EC isolates collected prospectively from hospital and clinical outcomes of patients with bacteriuria caused by ST131 vs. non-ST131 impact on clinical outcomes is poorly defined. We compared empiric treatment patterns β-lactamase (ESBL)-producing EC clinical isolates. The ST131- infections, and accounts for most fluoroquinolone (FQ)-resistant and extended-spectrum β-lactamase (ESBL)-producing EC clinical isolates. The ST131- H30 subclone was associated significantly with ESBL production, FQ resistance, illness severity, host compromise, and numerically lower clinical cure rates in symptomatic UTI.

Disclosures: Elizabeth B. Hirsch, PharmD, Merck; Grant/Research Support, Research Grant; Narbiva Therapeutics: Advisory Board; Paratek Pharmaceuticals: Advisory Board.

1439. Reducing the Number of Urine Cultures Performed Through Stringent Urinalysis Reflex Criteria

Emad Abu Sitta, MD; Anne Kegan, RN, CIC, BSN; Kelli Cole, PharmD, BCPS, BCACP; Heather Byrd, MLS (ASCP); Thomas Blomquist, MD, PhD; Geetha Suleyman, MD; University of Toledo Medical Center, Toledo, Ohio

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

1438. Escherichia coli (EC) ST131-H30 Clonal Group is Associated with Antimicrobial Resistance, Illness Severity, Host Compromise, and Non-Cure among Patients with Bacteriuria

Melanie T. Mahoney, BS; Hunter V. Briggman, BS; Brian Johnston, BS; Brian R. Raus, PharmD, BCPS; James R. Johnson, MD; Elizabeth B. Hirsch, PharmD; Elizabeth B. Hirsch, PharmD; College of Pharmacy, University of Minnesota, Minneapolis; 2Department of Medicine, University of Minnesota, Minneapolis, Minnesota; 3Medical University of South Carolina (MUSC), Charleston, South Carolina; 4Minnesota VA Medical Center, University of Minnesota, Minneapolis, Minnesota

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

Background. EC sequence type ST131 is the leading cause of extraintestinal EC infections, and accounts for most fluoroquinolone (FQ)-resistant and extended-spectrum β-lactamase (ESBL)-producing EC clinical isolates. The ST131-H30 subclone (H30) is responsible for most antimicrobial resistance within ST131; however, H30's impact on clinical outcomes is poorly defined. We compared empiric treatment patterns β-lactamase (ESBL)-producing EC clinical isolates. The ST131-H30 subclone caused by ST131 vs. non-ST131, and by H30 vs. non-H30 EC strains.

Methods. Phylogroups, ST131, H30, and CTX-M-type β-lactamase genes were detected by PCR for 142 non-duplicate EC isolates collected prospectively from hospitalized or emergency-department-attending adults with monomicrobial bacteriuria at a Boston academic medical center (August 2013–January 2014). Clinical and microbiologic data were collected retrospectively from electronic health records. Baseline characteristics, empiric treatment, and clinical cure rates were compared between ST131 vs. non-ST131, and H30 vs. non-H30, patient cohorts.

Results. Of 142 patients with EC bacteriuria, most (76%) were female and elderly (mean age 65.2 ± 21.2 years). Overall, 35% of isolates were ST131, of which 80% (39/49) were H30. Compared with other isolates, H30 isolates demonstrated a higher frequency of ESBL production (33% vs. 8%; P < 0.001) and FQ resistance (90% vs. 8%; P < 0.001). Patients with H30 isolates (vs. non-H30 isolates) were older (mean 73.4 ± 13.6 vs. 62.1 ± 27.7 years; P < 0.01), had higher median (interquartile range [IQR]) APACHE II scores (10 [4] vs. 8 [9.5]; P = 0.01), more commonly had underlying complicating conditions (100% vs. 83%; P = 0.03) and received in vitro-inactive empirical treatment (26% vs. 3%; P < 0.01), and had a numerically lower clinical cure rate (84% vs. 90%; P = 0.08). In contrast, patients with ST131 vs. non-ST131 isolates had similar median [IQR] APACHE II scores (9 [5] vs. 8 [9]), frequencies of symptomatic UTI (61% vs. 70%) and underlying complicating conditions (24% vs. 19%), and clinical cure rates (87% vs. 95%). Among patients with EC bacteriuria, the ST131-H30 subclone was associated significantly with ESBL production, FQ resistance, illness severity, host compromise, and numerically lower clinical cure rates in symptomatic UTI.

Disclosures: Elizabeth B. Hirsch, PharmD, Merck; Grant/Research Support, Research Grant; Narbiva Therapeutics: Advisory Board; Paratek Pharmaceuticals: Advisory Board.

1440. Prevalence and Regional Variation of in ESBLs and CRE Enterobacteriaceae (ENT) among Adults, Hospitalized Patients with ENT on a Urine Culture: A Multicenter Evaluation

Thomas Lodise, PharmD, PhD; Vikas Gupta, PharmD, BCPS; Kalvin Yu, MD; Kalpana Gupta, MD, MPH; Maureen Early, MT, MBA; Gang Ye, PhD; Jennifer Schranz, MD; Steven P. Golene, PharmD; Albany College of Pharmacy and Health Sciences, Albany, New York; Becton, Dickinson and Company, Franklin Lakes, New Jersey; VA Boston Healthcare System and Boston University School of Medicine, West Roxbury, Massachusetts; Narbiva Therapeutics US, Inc., King of Prussia, Pennsylvania

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

Background. Despite increased public health awareness of ESBLs and CRE, limited data exist regarding the true frequency of these resistant bacteria in urine cultures collected from adult patients in US hospitals. This study sought to quantify the prevalence and rates of ESBLs and CRE from urine cultures in adults hospitalized patients with ENT.

Methods. All hospitalized adults with a urine culture (first urine isolate of a specimen collected during a 30-day period) from 377 hospitals in 2018 were evaluated (BD Insights
Research Database, Becton, Dickinson & Company). ESBL was defined as an ENT that was ESBL-positive per commercial panels or intermediate or resistant (non-susceptible, [NS]) to a third-generation cephalosporin; CRE was defined as an ENT that was NS to imipenem, meropenem, doripenem or ertapenem. Urine isolates were classified as community-onset (CO) < 3 days of an inpatient admission and no previous admission within 3 days or hospital-onset (HO) ≥ 3 days post-admission or within 14 days of discharge) period. Prevalence and rates per 100 admissions were calculated overall, by hospital location (CO vs. HO), and by US Department of Health and Human Services (HHS) geographic region.

Results. In 2018, there were 193,476 non-duplicate ENT urine isolates across 4,623,333 admissions; 63.6% were E. coli (EC), 19.5% were K. pneumoniae/oxytocus (KPO), and 8.7% were P. mirabilis (PM). Overall, 12.6% were ESBL and 0.9% were CRE. Rate per 100 admissions was 0.484 and 0.037 for ESBL and CRE, respectively. Among CO, 11.8% were ESBL and ESBL rates per 100 admissions was 0.358; 0.7% were CRE and CRE rates per 100 admissions was 0.024. Among HO, 15.7% were ESBL and ESBL rates per 100 admissions was 0.126; 1.5% were CRE and CRE rates per 100 admissions was 0.013. Regional differences in both ESBL and CRE ENT were noted (table).

Conclusion. The prevalence of ESBLs/CRE among adult hospitalized patients with ENT in a urine culture was 13% and 1%, respectively. The % ESBL/CRE was higher among patients HO urine isolates whereas ESBL/CRE rates per 100 admissions were higher among patients with CO urine isolates. Considerable geographic varia

Disclosures. All authors: No reported disclosures.

1441. Comparison of Cefpodoxime vs. Oral Cefuroxime for Urinary Tract Infections at a Large Academic Medical Center
Hankoi Bao, PharmD1; Yanina Dubrovskaya, PharmD2; Shin-Pung (Poly) Jen, PharmD, BCPS-AQ ID, AATHP1; Xian Jie (Cindy) Chen, PharmD, BCPS1; Justin Siegfried, PharmD, BCPS1

John Papadopoulos, BS, PharmD, FCCM, BCCCP, BCNSP1; 1New York University Langone Health, New York, New York; 2New York University New York City, New York

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

Background. Cefpodoxime (CPD) and cefuroxime (CFX) are both oral cephalosporins indicated for urinary tract infection (UTI) treatment. CPD may have unfavorable pharmacokinetics (PK) given the lesser degree of renal excretion and urine concentration vs. CFX and risk of collateral damage. The objective of this study was to compare the efficacy and safety of these two agents for UTI treatment.

Methods. We conducted a retrospective evaluation among adult patients who received CPD or oral CFX for 248 hours for UTI treatment between January 2013 and July 2018. The primary outcome was the rate of subsequent UTI within 90 days following therapy. Safety outcomes included the rate of Clostridium difficile infection (CDI) and development of isolates resistant to third-generation cephalosporins (TGC) within 90 days. We also examined missed opportunities for antibiotic de-escalation in culture-positive patients.

Results. Of 747 patients assessed for study inclusion, 295 patients met eligibility criteria (CPD n = 165, CFX n = 130). Median age was 72 years (IQR 55–84) and 71% were female. More patients in the CPD vs. CFX group had pyelonephritis (29% vs. 11%, P = 0.0005) and were treated in the emergency department (42% vs. 16%, P = 0.0005). Escherichia coli was most commonly isolated (n = 139), followed by Klebsiella spp. The rate of subsequent UTI for CPD vs. CFX was 18% vs. 16%, P = 0.647 at median of 25 vs. 32 days, P = 0.399. CDI rate was 1% vs. 2%, P = 0.324 and resistance to TGC was detected in 4% vs. 1%, P = 0.068 for CPD vs. CFX, respectively. Missed opportunities to de-escalate antibiotics based on cultures were found in one-third of patients. After adjusting for multiple factors in multi

Conclusion. Despite less favorable urinary PK of CPD compared with CFX, this patient cohort, no differences in efficacy or safety between the two agents for UTI treatment were found. These findings warrant further exploration. Stewardship strategies for de-escalation from higher generation cephalosporins to narrow-spectrum antibiotics based on susceptibilities should be implemented.

Disclosures. All authors: No reported disclosures.

1442. Effect of Reflex Urine Culturing on Rates of Cultures and Infections in an Acute Care Hospital, Emergency Department, and Two Long Term Care Facilities
Chelsea Lynch, MPH, MSN, RN, CIC1; Andrea Appleby-Sigler, BS, MT(ASCP)2; Jacqueline Bork, MD2; Rohini Dave, PharmD2; Kimberly C. Gaes, PharmD2; Min Zhan, PhD2; Kathy Agnes, MS, RN, CIC2; Molly Sankey, MS, RN, CIC2

Dori Heath, BSN, CLSS-GB, RN, CIC3; Arlene Clark, MSHCA, RN, CIC3; Daniel Morgan, MD, MS4; VA Maryland Health Care System, Baltimore, Maryland; School of Pharmacy, University of Maryland, Baltimore, Maryland; School of Medicine, University of Maryland, Baltimore, Maryland; University of Maryland and VA Maryland Health Care System, Baltimore, Maryland

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

Background. Urine cultures are often positive in the absence of urinary tract infection (UTI) leading to unnecessary antibiotics. Reflex culturing decreases unnecessary urine culturing in acute care settings but the benefit in other settings is unknown.

Methods. This was a quasi-experimental study performed at a health system consisting of an acute care hospital, an emergency department (ED), and two long-term care (LT) facilities. Reflex urine culture was a urine analysis with > 10 white blood cells/high-power field. Urine cultures performed per 100 bed days of care (BDOC) were compared pre- (August 2016 to July 2017) vs. post-intervention (August 2017 to August 2018) using interrupted time series regression. Catheter-associated UTI (CAUTI) rates were reviewed to determine potential CAUTIs that would have been prevented.

Results. In acute care, pre-intervention, 894 cultures were performed (3.6 cultures/100 BDOC). Post-intervention, 965 urine cultures were ordered and 507 cultures were performed (1.8 cultures/100 BDOC). Reflex culturing resulted in an immediate 49% decrease in cultures performed (P < 0.001). The CAUTI rate 2 years pre-intervention was 1.8/1000 catheter days and 1.6/1000 catheter days post-intervention. Reflex culturing would have prevented 4/14 CAUTIs. In ED, pre-intervention, 1393 cultures were performed (5.4 cultures/100 visits). Post-intervention, 1959 urine cultures were ordered and 917 were performed (3.3 cultures/100 visits). Reflex culturing resulted in an immediate 47% decrease in cultures performed (P < 0.0015). In LT, pre-intervention, 257 cultures were ordered (0.4 cultures/100 BDOC). Post-intervention, 432 urine cultures were ordered and 354 were performed (0.5 cultures/100 BDOC). Reflex culturing resulted in an immediate 75% increase in cultures performed (P < 0.001). The CAUTI rate 2 years pre-intervention was 1.0/1000 catheter days vs. 1.6/1000 catheter days post-intervention. Reflex culturing prevented 1/13 CAUTIs.

Conclusion. Reflex culturing canceled 16%-51% of cultures ordered with greatest impact in acute care and the ED and a small absolute increase in LTC. CAUTI rates did not change although reflex culturing would have prevented 29% of CAUTIs in acute care and 8% in LTC.

Disclosures. All authors: No reported disclosures.

1443. N-Acetyl Cysteine Coadministration in Prevention of Amphotericin B–Induced Electrolytes Imbalances in Children
Kamile Arik, MD1; Ates Kara, MD2; Eda Karadag-Oncel, MD3; 1Kocsehir Research and Training Hospital, Ankara, Turkey; 2Hacettepe University, Ankara, Turkey; 3Izmir Tepcepk Research and Training Hospital, Izmir, Turkey

Session: 157. Urinary Tract Infections
Friday, October 4, 2019: 12:15 PM

Background. Amphotericin B (AmB) can cause electrolyte abnormalities, including hypokalemia, hypomagnesemia, hypernatremia, and metabolic acidosis; and most important, acute renal failure.

Methods. We conducted a randomized prospective cohort study from March 2012 to February 2018 at Hacettepe University Ihsan Doğramacı Children Hospital to children receiving AmB.

Results. A total of 87 patients including 37 patients with NAC and 50 patients without NAC received liposomal amphotericin B during the study period. Serum creatinine, blood urea nitrogen, phosphorus were not different statistically in both groups during the study period. Serum sodium, potassium, calcium, phosphorus, magnesium values taken on third day of AmB treatment were not statistically different in both groups. Mean serum magnesium value was higher in NAC received group on